Clinical data, trial updates, and in-depth explainers on the most promising obesity drug in development.
Eli Lilly offers early access to retatrutide, the triple-action weight loss drug showing dramatically greater results than Ozempic and Mounjaro.
Eli Lilly opens early access to retatrutide obesity drug before FDA approval for a limited number of patients.
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — status changed from ACTIVE_NOT_RECRUITING to COMPLETED. Pri...
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight — status changed from ACTIVE_NOT_RECRUIT...
Participants lost an average of nearly 56 pounds after 80 weeks on retatrutide
Retatrutide hit 22.6% weight loss in Phase 3 obesity trials
Retatrutide patients lost up to 49.6 lbs in Phase 3 trials, with additional cardiovascular disease outcomes data from TRIUMPH-3.
# Meta Description Retatrutide Phase 3 trial for obesity and chronic low back pain halts recruitment after reaching enrollment targets. (124 characters)
Trial NCT06982859 status changed from RECRUITING to ACTIVE_NOT_RECRUITING
Democratic lawmakers have questioned whether President Trump is the anonymous 79-year-old receiving a still-unapproved obesity drug via an FDA program
# Meta Description Fact-check of death claims linked to retatrutide, an unapproved weight loss injection, published July 9, 2026. (Character count: 119)
Eli Lilly announced it will file for FDA approval of retatrutide in the first quarter of 2027
# Meta Description Man dies from unapproved 'Reta' weight-loss drug; 76 others suffer serious injuries from the dangerous jab. (120 characters)
Retatrutide is known colloquially as 'Reta'
Retatrutide is described as a novel triple receptor agonist
# Meta Description Unapproved weight loss peptide tested at double labeled strength, creating enormous overdose risk, doctors warn. (123 characters)
Retatrutide is described as supposedly the final boss of weight-loss drugs
Retatrutide is manufactured by Eli Lilly and is not FDA approved
Eli Lilly and the FDA allowed a 79-year-old patient to gain extraordinary access to retatrutide through the FDA's compassionate use program
Six cases of acute liver failure linked to counterfeit retatrutide in Australia. Buyers purchasing from unlicensed sources face serious health risks.
A GP with over 20 years of experience reported treating a patient who had been taking unlicensed retatrutide
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia — status changed from ACTIV...
Eli Lilly shares jumped 4% on new retatrutide data, solidifying its dominance in the weight-loss market with a next-generation obesity treatment.
Retatrutide is described as a triple-hormone weight loss drug
The TRIUMPH trial (NCT07357415) status changed from RECRUITING to ACTIVE_NOT_RECRUITING as of June 9, 2026
Retatrutide has not been approved by the U.S. Food and Drug Administration
Retatrutide improved blood sugar control in trial participants
Retatrutide triple-acting drug reduces blood sugar and weight loss in type 2 diabetes patients, according to new trial results. (154 characters)
Retatrutide significantly reduced sleep apnea severity in adults with obesity
# Meta Description Retatrutide reduced A1C by up to 9.4% in phase 3 trial, outperforming semaglutide in type 2 diabetes patients. (127 characters)
Retatrutide phase 3 trial: 70 lbs average weight loss, 65% reached healthy BMI, knee pain cut 73% over 80 weeks.
Retatrutide, the most powerful GLP-1 ever developed, remains unlicensed and only available through illegal grey market sources.
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — status changed from ACTIVE_NOT_RECRUITING to COMPLETED. Primary comp...
Eli Lilly to present new retatrutide data at ADA conference, expanding treatment options for diabetes and obesity care.
Retatrutide achieves up to 24% weight loss, but doctors warn rapid results require close medical monitoring to prevent serious complications.
Retatrutide shows promise for slowing kidney disease progression in TRANSCEND-CKD trial, offering new treatment hope for CKD patients.
Foundayo oral GLP-1 outperformed semaglutide and dapagliflozin in type 2 diabetes without food or water restrictions. (153 characters)
CNBC reported strong Phase 3 results for Eli Lilly's retatrutide
# Meta Description Eli Lilly's retatrutide showed 70 lb weight loss over 80 weeks, outperforming Zepbound and Wegovy in clinical trials.
Retatrutide participants lost up to 85 pounds, surpassing results from Ozempic and Wegovy in early trials. (136 characters)
Eli Lilly's retatrutide achieved 70 lbs weight loss over 80 weeks in Phase 3 trials, with participants losing 28-30% of body weight.
Eli Lilly's retatrutide obesity drug cleared crucial trial data, positioning the company to file for FDA approval soon.
Retatrutide trial participants lost up to 85 pounds in 80 weeks, with 45.3% achieving weight loss levels comparable to bariatric surgery.
TRIUMPH-1 (n=2,339): all three doses met all endpoints. 45.3% of 12mg patients achieved ≥30% weight loss; 65.3% achieved BMI <30.
Phase 2 mean weight loss at 48 weeks: 12mg ~24.2% vs placebo ~2.1% (NEJM 2023; Jastreboff et al.)
Multi-receptor agonists and amylin therapies are transforming obesity treatment beyond GLP-1s, according to a May 2026 Nature review.
Study published May 14, 2026 in PubMed examines retatrutide's effects on lipid and metabolite profiles
TRIUMPH-4 Phase 3: discontinuation rates 12.2% (9mg) and 18.2% (12mg) vs 4.0% placebo at 68 weeks
Retatrutide eligibility: BMI ≥30 or ≥27 with hypertension/dyslipidemia. Excludes type 2 diabetes, prior bariatric surgery, and recent GLP-1 use.
27 triple-agonist programs are now competing in the post-GLP-1 obesity market across major pharma and biotech, according to PatentVest's May 2026 analysis.
Retatrutide's triple hormone receptor agonism addresses cardiovascular, kidney, and metabolic dysfunction simultaneously in CKM Syndrome patients.
Retatrutide Results: What Clinical Trial Data Tells Us About Real-World Outcomes — retatrutide results, retatrutide weight loss. Learn more at glp3md.com.
Retatrutide Crosses the Surgical Weight Loss Threshold — and the Patent Race Is On — retatrutide vs bariatric surgery, retatrutide glucagon. Learn more ...
Eli Lilly Raises 2026 Sales Forecast: What It Means for the Retatrutide Pipeline — Eli Lilly obesity drug, Lilly sales forecast 2026. Learn more at glp3...
Lilly Q1 2026 Earnings: What the Latest Report Reveals About Retatrutide — Lilly earnings retatrutide, retatrutide news 2026. Learn more at glp3md.com.
Retatrutide Weight Loss Results: What the Numbers Actually Mean — retatrutide results, retatrutide weight loss. Learn more at glp3md.com.
Retatrutide Cost: What to Expect When It Gets FDA Approval — retatrutide cost, best weight loss injection 2026. Learn more at glp3md.com.
Retatrutide availability before FDA approval — expanded access, compassionate use, and patient access programs explained. What Eli Lilly has and hasn't announced.
TRIUMPH-4 and TRIUMPH-5: What the Remaining Phase 3 Retatrutide Trials Are Testing — retatrutide phase 3 results. Learn more at glp3md.com.
GLP-3 Release Date: When Will Retatrutide Be Available to Patients? — retatrutide FDA approval. Learn more at glp3md.com.
What Is Retatrutide (GLP-3)? The Triple Agonist Obesity Drug Explained — retatrutide, triple agonist weight loss. Learn more at glp3md.com.
Retatrutide Phase 3 TRIUMPH Trial Results: What the Data Shows So Far — retatrutide triumph trial, triumph 1 retatrutide. Physician-supervised retatruti...
Retatrutide FDA Approval: Expected Date, NDA Filing Status, and Regulatory Timeline — retatrutide nda filing, retatrutide approval date 2026. Physician-...
TRIUMPH Trial Stops Recruiting: What the Phase 3 Retatrutide Study Closing Enrollment Means for Patients — TRIUMPH trial retatrutide, LY3437943 clinical...
Retatrutide Dosing and Weight Loss Results: What the Data Shows — retatrutide weight loss, retatrutide results. Physician-supervised retatrutide access ...
Retatrutide Side Effects: What Clinical Trials Reveal About Safety — retatrutide dosing, retatrutide. Physician-supervised retatrutide access at glp3md....
FDA Issues Warning Letters to Multiple Online GLP-1 Sellers for Unlawful Drug Sales — FDA GLP-1 enforcement 2025, unlawful GLP-1 telehealth. Physician-s...
How to Spot Fake GLP-1 Drug Suppliers Online — and Why Physician Supervision Matters — safe GLP-1 drugs online, compounded GLP-1 risks. Physician-superv...
New Study: Retatrutide Reduces Adipose Tissue Fibrosis Through Metabolic Reprogramming — retatrutide research 2026, retatrutide metabolic reprogramming....
Tirzepatide targets two receptors. Retatrutide targets three. We break down what that difference means for weight loss outcomes, side effects, and patient selection.
The Phase 3 TRIUMPH-4 trial set a new benchmark in obesity medicine. Here's a plain-language breakdown of the data, the methodology, and what comes next.
Only TRIUMPH-4 has reported results to date. Seven additional Phase 3 trials are expected to complete in 2026 before Lilly submits an NDA to the FDA.
Join thousands of patients waiting for physician-supervised access to retatrutide.
Join the Waitlist